Uscom

ASX MEDIA RELEASE

4C Quarterly Cash Report to 30 June 2021

Q4 customer receipts $1.22m - up 39% on Q3
FY21 total cash receipts $5.46m - up 19% on FY20
FY21 operating cash consumption $0.17m with cash on hand
New product approvals for China, Europe and Russia

SYDNEY, Australia, Wednesday 14th July 2021: Uscom Limited (ASX code: UCM) (the **Company** or **Uscom**) today released its Appendix 4C – Quarterly Cash flow report for the quarter ending 30 June 2021 (the **Quarter**) and Year to Date (**YTD**). The results disclosed in the attached Appendix 4C are in Australian dollars (AUD).

Summary:



9 year period

- CAGR 23%
- Increase in receipts 535%

Report:

The Uscom 4C for Q3 FY 2021 reports customer receipts of $1.22m for the quarter, up 39% from $0.88m in the preceeding quarter. Total cash receipts for FY21 were $5.46m, up 19% from $4.60m in FY20. FY21 customer receipts were $4.85m, up 21% from $4.02m in FY20. The global entity reported a net operating cash outflow of $0.17m for FY21, reduced 27% on FY20, with $1.71m cash on hand at 30th June 2021.

Administration and corporate costs were up ~$1m undermining global profitability, and reflected tax payments, corporate loans and issued shares accounted in lieu of cash. Staff costs were reduced by 5%.

Uscom

ASX MEDIA RELEASE

Commentary:

Uscom Executive Chairman, Professor Rob Phillips said "Q4 customer receipts increased 39% from Q3, while FY21 total cash receipts were up 19%. Critically we have achieved intermittent profitability and cash flow positivity, an inflection point for medical technology companies, in a difficult and unpredictable trading year. Theses results were despite the US and Europe both being inaccessible for more than half of FY21, and with global intermittent regional lockdowns restricting travel, access to hospitals, and sales, and a subsequent poor Q3. Uscom Europe and Uscom US are slowly emerging from the shadow of the pandemic with hospital activities recovering and sales forecasts for the coming half indicating an early rebound. Uscom China continues to perform profitably as we prepare for the entry to market of the newly NMPA approved BP+, and the anticipated approval of the SpiroSonic series of devices. Following a restructure, Uscom Europe tipped profitability before tax, a first in the subsidiary's history and despite the pandemic. In May we received CE Mark for the Uscom SpiroSonic AIR digital ultrasonic spirometer, allowing sale of the devices into Europe and a number of SE Asian countries. The AIR is an important technology for management of post-COVID syndrome and is receiving intense market interest as potentially 1B or more people worldwide may require post-COVID home lung function monitoring. More recently USCOM 1A was approved for sale in Russia. These approvals were delayed by approximately 12-18 months by the increasing demands of regulators worldwide and the disruption by the pandemic. Regulatory is expensive, time consuming and requires specialised regulatory teams to achieve, however this also increases the ultimate value of the approvals in the market. NMPA and FDA applications for SpiroSonic technologies are also progressing and we expect to have all our current products approved for sale through our growing global distribution web by the end of CY21. We anticipate these added products and expanded distribution network will boost global revenues, and we are currently in discussions with potential manufacturing and distribution partners worldwide to accelerate sales and ensure supply for the anticipated global demand in FY22."

Uscom manufactures and markets the **USCOM 1A**, the Uscom **BP+**, and the Uscom **SpiroSonic** digital ultrasonic spirometry technologies and the **VENTITEST** and **VENTITEST-S** ultrasonic ventilator calibration devices for optimising respiratory device performance.

* The amount included in line 6.1 of appendix 4C is the payment of fees to Directors.

References: Phillips RA. Post-COVID syndrome: After the Pandemic, the Pulmonary Consequences. 2021, June Health Europa. https://www.healtheuropa.eu/post-covid-syndrome-after-the-pandemic-the-pulmonary-consequences/109373/

Uscom

ASX MEDIA RELEASE

About Uscom

Uscom Limited (UCM): An ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

The USCOM 1A: A simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+: A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary **BP+ Reporter**, an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse pulse pressure waves and generate summary reports.

Uscom SpiroSonic digital multi-path ultrasonic spirometers: High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They require no calibration, are simple to disinfect, and are simple and accurate to use providing research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone apps and proprietary SpiroSonic software, **SpiroReporter**, with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, occupational lung disease and monitoring of pulmonary therapeutic compliance.

VENTITEST digital ultrasonic ventilator testing solution is a new system for testing ventilators. All ventilators require calibration to maintain the accuracy with which they measure the pressure, flow and volume of air they deliver. VENTITEST and VENTITEST-S, based on advanced SpiroSonic technology provides a testing solution that provides for simple and accurate testing, archiving, analysis and reporting to optimise ventilation performance.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Rob Phillips
Chairman
rob@uscom.com.au

Brett Crowley
Company Secretary

This announcement is approved for release to the ASX by the Board of Uscom Limited.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

USCOM LIMITED

ABN	**Quarter ended ("current quarter")**
35 091 028 090	30 June 2021

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (12 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	1,224	4,845
1.2	Payments for		
	(a) research and development	(162)	(739)
	(b) product manufacturing and operating costs	(100)	(724)
	(c) advertising and marketing	(175)	(617)
	(d) leased assets	(79)	(292)
	(e) staff costs	(395)	(1,642)
	(f) administration and corporate costs	(618)	(1,590)
1.3	Dividends received (see note 3)		
1.4	Interest received	8	32
1.5	Interest and other costs of finance paid	(8)	(12)
1.6	Income taxes paid	(5)	(5)
1.7	Government grants and tax incentives	-	579
1.8	Other (provide details if material)		
1.9	**Net cash from / (used in) operating activities**	**(310)**	**(165)**
2.	**Cash flows from investing activities**		
2.1	Payments to acquire:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment	-	(7)
	(d) investments		
	(e) intellectual property	(4)	(28)
	(f) other non-current assets		

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment		
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
2.6	**Net cash from / (used in) investing activities**	**(4)**	**(35)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)		
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options		
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(2)	(11)
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings		
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (provide details if material) - Unissued equity contributions received		
3.10	**Net cash from / (used in) financing activities**	**(2)**	**(11)**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	2,027	1,921
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(310)	(165)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(4)	(35)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(2)	(11)
4.5	Effect of movement in exchange rates on cash held		1
4.6	**Cash and cash equivalents at end of period**	**1,711**	**1,711**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	1,696	2,012
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (provide details) – Term Deposit	15	15
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**1,711**	**2,027**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	87
6.2	Aggregate amount of payments to related parties and their associates included in item 2	

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities		
7.2	Credit standby arrangements		
7.3	Other (please specify)		
7.4	**Total financing facilities**		

7.5	**Unused financing facilities available at quarter end**	

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (Item 1.9)	(310)
8.2	Cash and cash equivalents at quarter end (Item 4.6)	1,711
8.3	Unused finance facilities available at quarter end (Item 7.5)	
8.4	Total available funding (Item 8.2 + Item 8.3)	1,711
8.5	**Estimated quarters of funding available (Item 8.4 divided by Item 8.1)**	5.5

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 14 July 2021

Authorised by: The Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.